期刊文献+

血塞通胶囊对急性心肌梗死患者心脏重构与血清前胶原蛋白Ⅲ水平的影响 被引量:2

下载PDF
导出
摘要 目的采用血塞通胶囊联合化学药治疗冠心病心肌梗死,观察血清前胶原蛋白Ⅲ(PCⅢ)与心肌梗死心脏重构的关系,确定血塞通胶囊对冠心病急性心肌梗死血管损伤的治疗作用。方法将70例患者分为治疗组32例和对照组38例,均给予化学药治疗,治疗组加用血塞通胶囊。观察两组治疗前后PCⅢ水平变化,考察PCⅢ水平与心脏彩超左室舒张末内径(LVDEd)的关系。结果两组治疗后PCⅢ水平均较本组治疗前明显降低(均P<0.01)。对照组治疗后PCⅢ水平较治疗组高(P<0.05)。经统计学处理,PCⅢ水平与LVDEd呈明显正相关。结论加用血塞通胶囊比单纯运用化学药常规疗法降低PCⅢ水平效果明显,两种治疗方法均可降低PCⅢ水平。心肌梗死后PCⅢ水平与LVDEd呈直线相关关系。
作者 方居正 杨戈
出处 《医药导报》 CAS 2010年第11期1458-1459,共2页 Herald of Medicine
基金 国家自然科学基金资助项目(基金编号:30672765/C190402) 北京市自然科学基金资助项目(基金编号:7062058)
  • 相关文献

参考文献2

二级参考文献11

  • 1王爱莉,李晓斐.血清肝纤维化指标的临床应用和评价[J].中国现代医学杂志,2006,16(16):2540-2541. 被引量:2
  • 2Bolognese L,Carrabba N,Parodi G,et al.Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction.Circulation,2004,109:1121-1126.
  • 3Britten MB,Abolmaali ND,Assmus B,et al.Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction(TOPCARE-AMI):mechanistic insights from serial contrast-enhanced magnetic resonance imaging.Circulation,2003,108:2212-2218.
  • 4Claridge MW,Hobbs SD,Quick CR,et al.ACE inhibitors increase type Ⅲ collagen synthesis:a potential explanation for reduction in acute vascular events by ACE inhibitors.Eur J Vasc Endovasc Surg,2004,28:67-70.
  • 5Magga J,Puhakka M,Hietakorpi S,et al.Atrial natriuretic peptide,B-type natriuretic peptide,and serum collagen markers after acute myocardial infarction.J Appl Physiol,2004,96:1306-1311.
  • 6Sheehan FH,Bolson EL,Dodge HT,et al.Advantages and applications of the centerline method for characterizing regional ventricular function.Circulation,1986,74:293-305.
  • 7Latini R,Staszewsky L,Maggioni AP,et al.Delapril remodeling after acute myocardial infarction collaborative group.Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction:the delapril remodeling after acute myocardial infarction(DRAMI) trial.Am Heart J,2003,146:133.
  • 8Manginas A,Bei E,Chaidaroglou A,et al.Peripheral levels of matrix metalloproteinase-9,interleukin-6,and C-reactive protein are elevated in patients with acute coronary syndromes:correlations with serum troponin I.Clin Cardiol,2005,28:182-186.
  • 9Pollanen PJ,Lehtimaki T,Mikkelsson J,et al.Matrix metalloproteinase 3 and 9 gene promoter polymorphisms:joint action of two loci as a risk factor for coronary artery complicated plaques.Atherosclerosis.2005,180:73-78.
  • 10Nishikawa N,Yamamoto K,Masugama T,et al.Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation.Cardiovasc Rec.2003,57:766-774.

共引文献7

同被引文献40

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部